The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Genetic risk prediction company Genetic Technologies (GTG) has tapped U.S. institutions for another $2.3 million
  • The fresh capital will be raised through the issue of over 700,000 American Depositary Shares at $2 each
  • Each share, however, represents 600 Genetic Technology shares, meaning the company will issue over four million new shares at 0.53 cents each to raise the funds
  • Today’s capital raise comes less than three weeks after Genetic Technologies raised $2.9 million through similar means
  • The company said the money will be used to fund capacity for COVID-19 testing and develop some polygenic risk score testing
  • GTG shares went unmoved today, closing grey at 0.6 cents each

Genetic risk-assessment company Genetic Technologies (GTG) has tapped institutional investors in the States for yet another US$1.44 million.

The capital raise is worth roughly A$2.3 million based on the current exchange rate and comes less than three weeks after the company announced a US$1.8 million raise in early April.

The latest capital raise will follow a similar model to the early April funding. Institutional investors will be issued roughly 722,500 American Depositary Shares (ADSs), which each represent 600 GTG shares. The ADSs will each be sold for $2.

This means roughly 4.3 million new GTG shares will be put on offer at 0.53 cents each.

Genetic Technologies said it would be using the new cash to fund capacity for COVID-19 testing, develop some polygenic risk score testing and, of course, for general working capital.

Genetic technologies saw an opportunity for its tech brought about by the coronavirus pandemic and made the call to fast-track its Consumer Initiated Testing (CIT) platform earlier this month.

Essentially, GTG’s tech is designed to work out how at-risk a patient is for severe conditions and diseases like cancers and diabetes.

Once a patient is assessed, the tech can then recommend lifestyle changes, medications, or frequent screening.

The CIT platform lets a patient order and conduct a test themself while maintaining remote clinician oversight.

With COVID-19 stretching healthcare systems to their limits, Genetic Technologies’ CIT platform is designed to ease the burden on primary care clinicians while making sure worried patients still receive testing.

It seems with the decision to fast-track the launch of the self-testing system, Genetic Technologies is in need of some fast cash.

Despite the discounted capital raise, shares in GTG stayed grey today, continuing to trade for 0.6 cents each.

GTG by the numbers
More From The Market Herald

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…

Little Green Pharma’s strong half-year performance signals robust Cannabis growth in Europe and Australia

Little Green Pharma (ASX:LGP) released its half-yearly financial report, showing revenue from ordinary cannabis sales is…

4DMedical inks MOU with Philips to expand XV Technology sales in North America

4DMedical (ASX:4DX) has signed a MOU with Philips to expand sales opportunities for its XV Technology…